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Engagement of intercellular adhesion molecule-1 (ICAM-1) on endothelial c ls (ECs) by 
anti-ICAM coated beads generates vesiculization via cell adhesion molecule (CAM)-
mediated endocytosis, a clathrin-/caveolae-independent pathway involving Na+/H+ 
exchanger 1 (NHE1). ICAM-1 itself plays a key role in transendothelial migration (TEM) 
of leukocytes, particularly via the transcellular route. This involves endothelial endocytic 
vesicles that coalesce into transmigration pores, through which leukocytes transmigrate 
without disrupting EC junctions. The contribution of CAM-mediated endocytosis to the 
formation of docking sites and vesicular structures supporting TEM was explored in this 
study. Results show that the ICAM-1/NHE1-dependent CAM-mediated pathway 
associates with acid sphingomyelinase and ceramide. This supports plasmalemma 
deformability and cytoskeleton rearrangement, bridging these events to the formation of 







ROLE OF ACID SPHINGOMYELINASE IN ICAM-1/NHE1-DEPENDENT 







Thesis submitted to the Faculty of the Graduate School of the 
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 


















Professor Silvia Muro, chair 
Professor Volker Briken 
Professor Wenxia Song 


















I would like to thank my advisor, Dr. Silvia Muro for her invaluable support and 
guidance during the course of this project. I acknowledge Dr. Ming Meng, Dr. Carmen 
Garnacho, Rishi Chadha, and Dr. Tridib Bhowmick for their help and contribution to this 
project. Finally, I thank the support of my family and friends as I continue forward with 
my Ph.D. research. 
My graduate studies during the course of this work were supported by a Bridge to the 
Doctorate Fellowship and a Graduate Research Fellowship, both from the National 
Science Foundation. Laboratory funds included the Minta Martin Foundation, American 
Heart Association Beginning Grant-in-Aid 09BGIA2450014 and National Institutes of 
Health R01 HL098416. 
iii 
 
Table of contents 
List of tables.............................................................................................................................. v 
List of figures............................................................................................................................ vi 
List of abbreviations................................................................................................................. vii 
Chapter 1: Background and significance.................................................................................. 1 
1.1. Intercellular adhesion molecule-1 (ICAM-1).................................................................... 1 
1.2. Leukocyte transmigration.................................................................................................. 3 
1.3. ICAM-1 in leukocyte transendothelial migration.............................................................. 6 
1.4. CAM-mediated endocytosis.............................................................................................. 7 
1.5. Scope of the research......................................................................................................... 10 
Chapter 2: Materials and methods............................................................................................ 11 
2.1. Antibodies and reagents..................................................................................................... 11 
2.2. Cell culture......................................................................................................................... 11 
2.3. Quantification of leukocyte transmigration across endothelial cell monolayers............... 12 








2.6. CAM-mediated endocytosis of anti-ICAM beads and actin remodeling.......................... 16 
2.7. CAM-mediated endocytosis in vivo................................................................................... 16 
2.8. Statistics............................................................................................................................. 17 
Chapter 3: Results..................................................................................................................... 18 
3.1. Effect of disrupting lipid domains or CAM-mediated endocytosis on leukocyte 
transmigration across endothelial cells..................................................................................... 
 
18 
3.2. Lipid domains and CAM-mediated endocytosis in pre-transmigration interactions 
between leukocytes and endothelial cells................................................................................. 
 
21 
3.3. Association of lipid domains and the sphingomyelin/ceramide pathway with 
endothelial docking structures induced by ICAM-1 engagement............................................ 
 
26 
3.4. Recruitment of acid sphingomyelinase to endothelial docking-like structures……......... 32 
3.5. Effect of impairing acid sphingomyelinase on CAM-mediated endocytosis and 
associated cytoskeletal rearrangement...................................................................................... 
 
35 
3.6. Acid sphingomyelinase in pre-transmigration interactions between l ukocytes and 
endothelial cells........................................................................................................................ 39 
iv 
 
Chapter 4: Discussion............................................................................................................... 41 
Chapter 5: Conclusions and future directions........................................................................... 48 





List of tables 
Table 1. Comparison of endocytic pathways............................................................................ 8 

























List of figures 
Figure 1. Structure of ICAM-1............................................................................................... 1 
Figure 2. Main steps of leukocyte recruitment at the endothelium and transendothelial 
migration................................................................................................................................. 4 
Figure 3. CAM-mediated endocytosis and signaling.............................................................. 9 




Figure 5. Endothelial binding and transmigration of white blood cells........................ 20 




Figure 7. Pre-transmigratory interaction of white blood cells and endothelial cells.............. 25 
Figure 8. Induction of endothelial docking-like structures upon ICAM-1 engagement by 
anti-ICAM beads..................................................................................................................... 27 




Figure 10. Quantification of enrichment of molecules at the endothelial plasmalemma in 
areas of ICAM-1 engagement by anti-ICAM beads............................................................... 30 
Figure 11. Effect of amiloride on the formation of ICAM-1-rich endothelial docking-like 
structures by anti-ICAM beads............................................................................................... 
 
31 
Figure 12. Intracellular redistribution of endothelial acid sphingomyelinase upon ICAM-1 
engagement by anti-ICAM beads........................................................................................... 
 
33 
Figure 13. Plasmalemma distribution of endothelial acid sphingomyelinase upon ICAM-1 
engagement by anti-ICAM beads........................................................................................... 
 
34 
Figure 14. Recruitment of molecules at sites of anti-M6PR bead binding………................. 35 
Figure 15. CAM-mediated endocytosis in vivo...................................................................... 37 




Figure 17. Acid sphingomyelinase enrichment at the interface between hite blood cells 
and endothelial cells and its role in WBC sampling............................................................... 
 
40 
Figure 18. Induction of transcellular pore-like structures by ICAM-1 engagement............... 44 
Figure 19. Model for the contribution of CAM-mediated endocytosis and the 







List of abbreviations 
ASM, Acid sphingomyelinase 
CAM, Cell adhesion molecule 
Cdx, Methyl-β-cyclodextrin 
D1-D5, Domains 1 through 5 of ICAM-1 




HUVEC, Human umbilical vein endothelial cell 
ICAM-1, Intercellular adhesion molecule-1 
LFA-1, Lymphocyte function-associated antigen 1 
M6PR, Mannose-6-phosphate receptor 
MAPK, Mitogen-activated protein kinase 
MDC, Monodansylcadaverine 
MLEC, Mouse lung endothelial cell 
NHE1, Na+/H+ exchanger 1 
PECAM-1, Platelet-endothelial cell adhesion molecule-1 
PI3K, Phosphatidylinositol 3-phosphate kinase 
PMN, Polymorphonuclear leukocyte 
ROCK, Rho-dependent kinase 
ROS, Reactive oxygen species 
SDF-1α, Stromal cell-derived factor 1-alpha 
SEM, Scanning electron microscopy 
TEM, Transendothelial migration 
TNFα, Tumor necrosis factor α 
VCAM-1, Vascular cell adhesion molecule-1 
VLA-4, Very late antigen 4 
WBC, White blood cell 
1 
 
Chapter 1: Background and significance 
1.1. Intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is a type I transmembrane 
glycoprotein of the immunoglobulin superfamily expressed mainly on the plasmalemma 
of endothelial cells (ECs)1,2. Its expression is constitutive, but upregulated during 
inflammatory conditions by agents such as tumor necrosis factor α (TNFα)3. The 
extracellular region of ICAM-1 consists of 5 discrete immunoglobulin-like domains (D1 
at the N-terminus, through D5) arranged linearly in a rod-like conformation that extends 
20 nm away from the plasmalemma4,5. As such, ICAM-1 is displayed in a manner 
suitable for its function as an adhesive receptor for leukocyte integri s αLβ2 and αMβ2 
which can interact with D1 and D3, respectively6,7 (Fig. 1). 
 
 
Figure 1. Structure of ICAM-1. Intercellular adhesion molecule-1 (ICAM-1) on the plasma membrane. 
Domains (D) 1 through 5 are found on the N-terminal extracellular side of the plasmalemma. A 
transmembrane domain is followed by a C-terminal short cytosolic tail. Binding sites for leukocyte 




The cytosolic tail of ICAM-1 is short, consisting of 28 residues8, and lacks conventional 
protein-protein interaction domains. However, the sequence contains several positively-
charged residues and a tyrosine residue, which account for its protein-binding and 
signaling activities9-15. In particular, most proteins that bind the cytosolic tail of ICAM-1 
serve as cytoskeleton adaptors: α-actinin11, β-tubulin12, and erzin16. Radixin and moesin, 
the two other members of the ezrin-radixin-moesin (ERM) family of actin adaptors, have 
been found to colocalize with ICAM-117,18. These interactions with members of the 
cytoskeleton or cytoskeleton-adaptor proteins appear to be important for ICAM-1 
distribution on the plasma membrane: ICAM-1 is normally found enriched in microvillar 
structures, while deletion of its cytoplasmic domain shifts distribution to homogeneous 
on the cell surface11,16,19. Scanning electron microscopy (SEM) reveals that this 
redistribution is itself associated with a loss in microvilli structures19. This suggests a link 
between ICAM-1 and formation of membrane protrusions. 
Signal transduction is also associated with the cytosolic residues of ICAM-1. 
Engagement of ICAM-1 at the surface of ECs using cross-linked antibodies (known as 
multivalent engagement/binding) activates xanthine oxidase activity, generating reactive 
oxygen species (ROS) that in turn activate Src-kinases20-23. ICAM-1 cross-linking also 
activates small GTPase Rho17,18,24,25, RhoA18 and perhaps other Rho proteins15,20, and 
mitogen-activated protein kinases (MAPK)23,26. In turn, p38 MAPK phosphorylates 
HSP27 and this leads to cytoskeletal rearrangement27. Along with MAPK, cytoskeleton-
associated proteins ezrin, cortactin, focal adhesion kinase, paxillin, and p130Cas are also 
phosphorylated downstream of Src5,20,22,23, consistent with multiple reports that cross-
linking ICAM-1 elicits rearrangement of the actin cytoskeleton28-31. Wittchen has 
3 
 
recently summarized the current signaling paradigms associated with ICAM-1 
signaling32. These events occur in parallel to ICAM-1 redistribution to detergnt-resistant 
membrane fractions, an event likely to be important for signaling through ICAM-1. For 
instance, Src activation seems to depend on Src-homology domain 2 containing 
phosphatase 2, which binds to ICAM-1 upon cross-linking and entry into detergen -
resistant membrane fractions9,10. Specialized lipid domains might serve as rigid platforms 
for localized maintenance of ICAM-1-dependent signaling events and cytoskeletal 
remodeling33. Hence, it is expected that the physiological functions of ICAM-1 will be 
associated with such signaling pathways, specialized platforms, and the membrane 
protein/lipid composition and morphological changes associated with these domains. 
 
1.2. Leukocyte transendothelial migration. Recruitment of leukocytes to inflammatory 
sites is described as a sequential series of events that results in transendothelial migration 
(TEM), or crossing of the EC barrier34,35. In this model, leukocytes are recruited by 
tethering, followed by rolling interactions, strong adhesion, lateral crawling, and TEM, 
which can occur through a paracellular or a transcellular route32,34,36 (Fig. 2). The initial 
steps of tethering and rolling involve the interaction of leukocyte L-s lectin or EC E- and 
P-selectins with P-selectin glycoprotein ligand 1 and other glycosylated ligands expressed 
on either leukocytes or ECs34,37-39. Although rolling can also be supported by leukocyte 
integrin interactions with EC surface proteins34,40,41, these binding events are crucial for 
arrest and firm adhesion42,43. The most commonly studied interactions in firm adhesion 
are those of leukocyte integrins αLβ2 (lymphocyte function-associated antigen 1, LFA1) 
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and α4β1 (very late antigen 4, VLA-4) with ICAM-1 and vascular cell adhesion molecule-
1 (VCAM-1), respectively44,45. 
 
 
Figure 2. Main steps of leukocyte recruitment at the endothelium and transendothelial migration. 
Leukocytes undergo selectin-mediated tethering and rolling, followed by integrin-mediated firm adhesion, 
which leads to formation of endothelial docking struc ures (star). After firm adhesion, crawling (not shown) 
involves lateral migration of leukocytes to sites suitable for transmigration. Finally, transendothelial 
migration can occur by two means. The transcellular path involves tractive forces by docking structures, 
and EC vesicular fusion into transcellular pores. The paracellular path involves opening of endothelial cell-
cell junctions and crossing of the endothelium through these junction openings. 
 
Regarding transmigration, paracellular TEM involves dissociation of cell junctions 
between ECs, and passage of leukocytes in between opened junctions34,46. Transcellular 
TEM is independent of junction opening, where a leukocyte moves across the body of an 
individual EC in a process that involves fusion of endothelial vesicles into a so-called 
transcellular pore, through which leukocytes migrate47-50. 
TEM features notable membrane changes at the protein/lipid composition and 
morphological levels in both leukocytes and the EC plasmalemma: Following arrest, 
leukocytes crawl laterally on the surface of ECs, which changes leukocyte morphology 
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from round to flattened19,51,52. Along with this, leukocytes extend protrusions (~0.2-1 µm 
in diameter and up to several microns in length53) against the plasmalemma of ECs, 
which is thought to allow leukocytes to probe for sites suitable for transmigration47,53. 
Simultaneously, ECs extend protrusions around leukocytes, which form a structure 
known as the transmigratory cup, or docking structure48,54,55. The formation of this 
structure, which is enriched in ICAM-1, likely due to profuse LFA-1-ICAM-1 
interactions, is associated with rearrangement of the actin cytoskeleton to form stress 
fibers, and depends on the cytosolic tail of ICAM-119,55,56. The maintenance of these large 
regions of specific molecular enrichment is associated with protein/lipid rearrangement to 
form specialized lipid domains at the plasma membrane that allow for ICAM-1-
dependent signaling events. This is manifested in the enrichment of ICAM-1, VCAM-1, 
tetraspanin CD9, actin, RhoG, ezrin, and moesin48,54-56, and a redistribution of ICAM-1 to 
detergent-resistant membrane fractions57. 
Accompanying the formation of transmigratory cups is the generation of EC plasma 
membrane vesicles of 200 nm to 1 µm in diameter that coalesce into larger structures, 
with the eventual formation of a pore that transverses the entire EC body, through which 
leukocytes transmigrate49,53. This structure is known as the transcellular pore and can be 
as large as 6 µm in diameter53. Although some data suggest the involvement of caveolar 
endocytosis and/or the related vesiculo-vacuolar organelle during this phenomenon49, 
some reports have shown no or partial association between the transcellular pore and 
other structures associated with TEM and caveolin48,53,58. Thus, the nature and regulation 




1.3. ICAM-1 in leukocyte transendothelial migration. Leukocytes bind ICAM-1 
through their integrins LFA-1 and αMβ2 (macrophage-1 antigen, Mac-1)
6,44,59. Initially, 
this interaction was characterized as exclusively adhesive, particul ly at the TEM stage 
of firm adhesion, but signaling functions have now been attributed to ICAM-1 binding by 
leukocytes. Since a single leukocyte exhibits multiple copies of these integrins, it can 
engage multiple copies of ICAM-1. Thus, signaling events observed during ICAM-1 
multivalent binding by antibodies, as described in Section 1.2, match with those 
associated with leukocyte binding and TEM60. For instance, inhibition of Rho activity 
diminishes lymphocyte migration through brain cells in an ICAM-1-dependent manner24. 
Binding of polymorphonuclear leukocytes (PMNs) to ECs increases intracellular Ca2+, 
and disallowing Ca2+ increase prevents transmigration but not binding61. PMN adhesion 
to ECs induces rearrangement of the actin cytoskeleton30,31, prevented by inhibition of 
p38 MAPK26. Finally, cortactin phosphorylation is essential for leukocyte TEM62. 
More specifically, the role of ICAM-1 in leukocyte transcellular TEM has become well 
recognized. TNFα activation of ECs to induce ICAM-1 overexpression increases the 
percentage of PMNs that migrate using the transcellular route50. Further, blocking or 
deleting the cytoplasmic domain of ICAM-1 reduces transcellular TEM events, 
suggesting that transcellular migration depends on ICAM-1 signaling nd/or association 
with actin50. During transcellular TEM, ICAM-1 becomes internalized and undergoes 
transcytosis to the basal membrane of ECs49, which is likely a manifestation of 
transcellular pore aperture, as regions where podosomes probe EC membran  and 
transcellular pores form, are enriched in ICAM-1. 
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Interestingly, formation of plasmalemma engulfing structures, invaginations and 
coalescing vesicles, as well as upstream signaling and cytoskeletal restructuring observed 
during ICAM-1 engagement by antibodies are reminiscent of the events elicited during 
ICAM-1-specific leukocyte binding to ECs prior to transmigration. This points to a 
possible role for ICAM-1-mediated formation of endocytic vesicles during leukocyte 
TEM. 
 
1.4. CAM-mediated endocytosis. As described above, ICAM-1 serves as an adhesive 
molecule for leukocytes during inflammation, and subsequent work revealed signaling 
properties associated with this function. Studies on the use of ICAM-1 for endothelium-
targeted delivery of therapeutics led to the discovery of its role as an endocytic re eptor29. 
Cell adhesion molecule (CAM)-mediated endocytosis is a non-classial endocytic 
pathway (Table 1) elicited upon engagement of multiple copies of ICAM-1 (Fig. 3). 
Multivalent engagement can be achieved by the interaction between antibody-coated 
micro- or nanoparticles and ICAM-1 on the EC surface, which is followed by Na+/H+ 
exchanger 1 (NHE1)-dependent endocytosis of particles and intracellular trafficking to 
early endosomes and then lysosomes29,63,64. Recent studies in our group have shown that 
























+ + + - - + Cav, Clat 
Receptor-mediated + + - + + + M 
Dynamin-2 + + - + + + M 
NHE - - + - - + 
C, F, Cav, 
Clat 
PKC + + + + + + n 
Actin + + + + + + n 
Actin cup + + + - - - C, F, M 
Microtubules + - + + + - 
C, M, Cav, 
Clat 
Src kinase - + + + + + C 
PI3 kinase + + + ? - - C, F, M 
Rho/ROCK + - ? ? ? + F 
Colocalization with 
caveolin-1 





- - - - + - Clat 
Sensitive to 
filipin/genistein 
? ? - + - - Cav 
Sensitive to 
LatA/CytD 
+ + + + + 
+ (LatA) / 
- (CytD) 
C, F, M, Cav, 
Clat 
Adapted from Caron and Hall
67
, and Muro et al.
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+, required for uptake/event observed; –, not required for uptake/event not observed; ?, no definitive data found in the literature/not previously tested. 
MDC, monodansylcadaverine; LatA, latrunculin A; CytD, cytochalasin D;  C, complement receptor (CR)-mediated phagocytosis; F, FcR-mediated phagocytosis; 
M, macropinocytosis;  Cav, caveolae-mediated endocytosis; Clat, clathrin-mediated endocytosis; CME, CAM-mediated endocytosis; n, none. 
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Similar to clathrin- and caveolae-dependent endocytosis, CAM-mediated endocytosis is 
dynamin-dependent29. However, fluorescently labeled anti-ICAM beads do not colocalize 
with clathrin heavy chain or caveolin-1 during the process of internalization or 
intracellular trafficking29. This is confirmed by transmission electron microscopy images 
of mouse endothelium, which show that anti-ICAM beads are contained in EC 
invaginations and vesicles not associated with typical morphological features of these 
two classical endocytic pathways, such as caveolar pits and clathrin coats66. Further, 
pharmacological inhibitors of caveolae- (filipin and genistein) or clathrin-mediated (K+ 
depletion and monodansylcadaverine, MDC) endocytosis do not inhibit internalization 
elicited by multivalent binding of ICAM-129. 
 
Figure 3. CAM-mediated endocytosis and signaling. CAM-mediated endocytosis is initiated upon 
multivalent binding of ICAM-1 by anti-ICAM-coated particles. ICAM-1 engagement elicits the recruitment 
of NHE1, which is itself an adaptor of the actin cytoskeleton. Signaling through Rho/ROCK, PKC, and Src 
elicits dynamin-dependent endocytosis. Internalized v sicles fuse into early endosomes, where ICAM-1 
dissociates from anti-ICAM beads, and recycles back to the plasma membrane. Early endosomes 
maturate/fuse with lysosomes in an NHE6-dependent manner. The final trafficking destination of beads is 
the lysosome. Not shown is the alternative pathway of transcytosis, which has been shown to occur in 
epithelial cells65.  
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Due to the close association between CAM-mediated endocytosis and the ac in 
cytoskeleton, this pathway shares certain features with macropinocytosis and 
phagocytosis, in particular protein kinase C (PKC) dependence, as PKC inhibitors 
bisindolylmaleimide-1 (BIM-1) and 1-(5-isoquinoline-sulphonyl)-2-methylpiperazine (H-
7) reduce, and PKC stimulator phorbol 12-myristate 13-acetate (PMA, applied in a short-
time incubation) increases, internalization of anti-ICAM beads29. However, CAM-
mediated endocytosis does not exhibit the formation of actin cups or membrane ruffling, 
as the two other pathways29. Furthermore, CAM-mediated endocytosis is independent of 
microtubules for internalization to occur, unlike macropinocytosis, and of 
phosphatidylinositol 3-phosphate kinase (PI3K) signaling, unlike phagocytosis29. A  
observed with cross-linked antibodies, which also multivalently engage ICAM-1, 
multivalent engagement of ICAM-1 with anti-ICAM beads leads to particular signaling 
events. CAM-mediated endocytosis is associated with Rho-dependent kinase (ROCK), 
PKC, and Src kinase29, culminating in remodeling of the actin cytoskeleton into stress 
fibers. Despite considerable characterization of CAM-mediated endocytosis, this pathway 
has not been studied in the context of its potential physiological function. Thus, it is still 
unknown if this pathway of endocytosis is relevant to the biological function of ICAM-1. 
1.5. Scope of the research. Based on the evidence presented, this project aims at 
investigating the possible association between CAM-mediated endocytosis and leukocyte 
transmigration. The main hypothesis claims that events observed during ICAM-1 
engagement on the endothelium, which result in CAM-mediated formation of vesicles, 




Chapter 2: Materials and methods 
2.1. Antibodies and reagents. Monoclonal antibodies to the extracellular domain of 
human or mouse ICAM-1 were R6.5 and phycoerythrin-conjugated LB-2 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), or YN1, respectively64,66. Monoclonal antibodies 
to mouse platelet-endothelial cell adhesion molecule-1 (PECAM-1), or human VCAM-1, 
VLA-4, LFA-1 integrin, or ceramide were from BD Biosciences (Franklin Lakes, NJ), 
EMD Chemicals (Gibbstown, NJ), Millipore (Billerica, MA), Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA), and Sigma-Aldrich, Inc. (Saint Louis, MO). Polyclonal antibodies 
to human acid sphingomyelinase (ASM), tetraspanin CD9, NHE1 or ganglioside GM1 
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and EMD Chemicals 
(Gibbstown, NJ). Secondary antibodies were from Jackson Immunoresearch 
Laboratories, Inc. (West Grove, PA) and Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Polystyrene-latex beads were from Polysciences, Inc. (Warrington, PA). BODIPY® 
FL C12-sphingomyelin and Texas Red-labeled phalloidin were from Molecular Probes, 
Inc. (Eugene, OR). All other reagents were from Sigma-Aldrich, Inc. (Saint Louis, MO). 
 
2.2. Cell culture. Human umbilical vein endothelial cells (HUVECs) purchased from 
Lonza Walkersville, Inc. (Walkersville, MD) were cultured in M-199 medium 
supplemented as described29. Mouse lung endothelial cells (MLECs) were isolated from 
wild-type C57BL/6 (The Jackson Laboratory, Bar Harbor, ME) or ASM−/− mice68 (kindly 
provided by Dr. Edward Schuchman, Mount Sinai School of Medicine, New York, NY) 
by cutting lungs into 1-2 mm fragments, followed by digestion overnight at 4°C in 1 
mg/mL collagenase and filtration through a 40 µm nylon mesh69. Cells were isolated by 
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incubation with anti-PECAM Mec13.3-coated Dynabeads® (Invitrogen Corporation, 
Carlsbad, CA) for 30 minutes at 4°C, and cultured in supplemented DMEM medium69. 
Isolation of MLEC from mice adjusted to IACUC regulations. For experiments, ECs 
were seeded on 1%-gelatin-coated glass coverslips or 8-µm pore Transwell® filters 
(Corning Inc., Lowell, MA), as indicated. Cells were treated for 16 hours with 10 ng/mL 
TNFα (BD Biosciences, Franklin Lakes, NJ) to induce endothelial activation and up-
regulation of ICAM-1 expression.  
Wild-type peripheral-blood leukocytes (herein called white blood cells, WBCs) were 
obtained from healthy volunteers (under IRB-approved protocols) following a standard 
protocol for lymphocyte isolation. Shortly, isolation was done in 0.109 M sodium citrate 
using density gradient centrifugation over Ficoll-PaqueTM PLUS (GE Healthcare 
Amersham Biosciences Corp., Piscataway, NJ), followed by incubation of WBCs as non-
adherent cells in RPMI-1640 supplemented with 10% fetal bovine serum (Mediatech, 
Inc., Manassas, VA). Non-migratory K562 erythroid leukemia cells were obtained from 
Sigma-Aldrich (Inc., Saint Louis, MO) and cultured in supplemented RPMI. Prior to 
experiments, WBCs or K562 cells were activated with 50 U/ml interleukin 2 (IL-2) for 
72 hours.  
 
2.3. Quantification of leukocyte transmigration across endothelial cell monolayers. 
IL-2-activated WBCs were added at 1.5-WBC to 1-HUVEC ratio to the upper chamber 
above a confluent monolayer of TNFα-activated HUVECs grown on 8-µm pore 
Transwell® filters. Recombinant lymphocyte chemoattractant stromal cell-derived factor 
1-alpha (SDF-1α; R&D Systems, Inc., Minneapolis, MN) was added at 200 ng/mL to the 
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chamber under HUVECs. Transmigration was assessed by counting WBCs from the 
bottom chamber after incubation with HUVECs for 30 minutes at 37°C. For inhibition, 
HUVECs were pre-treated with 3 mM amiloride, which blocks CAM-mediated 
endocytosis, or 1 µg/mL filipin or 5 mM methyl-β-cyclodextrin (Cdx) to chelate 
cholesterol, and the inhibitors were maintained through the experiment. Alternatively, 
WBCs were pre-treated with 40 ng/µL anti-VLA-4 (to block binding to VCAM-1) or 
anti-LFA-1 (to block binding to ICAM-1), then washed and incubated over HUVECs.  
Although transmigration of leukocytes across ECs has been shown to be enhanced under 
flow conditions, we used this TEM model based on Transwell® filters (which requires 
static conditions) to maximize sensitivity of detection: all transmigrated WBCs are 
accounted for in this system, whereas microscopy imaging of transmigration under flow 
only permits to visualize a selected endothelial area.  
 
2.4. Imaging leukocyte adhesion and pre-transmigratory interactions with 
endothelial cells. IL-2-activated WBCs were stained with 4 µM green fluorescent calcein 
(Molecular Probes, Inc., Eugene, OR), washed, and added over TNFα-activated HUVECs 
growing on glass coverslips at 1.5-WBC to 1-HUVEC ratio. The cells were incubated for 
30 minutes at 37°C in 200 ng/mL SDF-1α, followed by fixation with 2% cold 
paraformaldehyde and then washing to remove non-adhered WBCs. For inhibitio , 
HUVECs were pre-treated with 3 mM amiloride, 1 µg/mL filipin, 5 mM Cdx, or 50 µM 
imipramine (to inhibit ASM), and the inhibitors were maintained through the experiment. 
Samples were stained after fixation using blue-fluorescent labeled-anti-ICAM (to better 
image the EC surface in experiments looking at WBC-EC interactions), or anti-ASM plus 
14 
 
a secondary antibody labeled with Texas Red (in experiments looking at ASM 
enrichment at the WBC-EC interface).  
Samples were analyzed by phase-contrast and fluorescence microscopy (Olympus IX81, 
Olympus, Inc., Center Valley, PA) with a 40x oil immersion objective (UPlanApo, 
Olympus, Inc., Center Valley, PA). Micrographs were taken for several z-sections with 
an ORCA-ER camera (Hamamatsu Corporation, Bridgewater, NJ) and SlideBook™ 4.2 
(Intelligent Imaging Innovations, Inc., Denver, CO). Total amount of WBCs left after 
washes on the EC monolayer were quantified. Rounded WBCs were scored as simply 
“adhered” cells and flat spread WBCs (which could have been arrested or crawling) were 
scored as “sampling” cells. Both adhered and sampling WBCs were additionally located 
at the either the EC border (in contact with the border at any extent) or away from it (EC 
“body”). Location of WBCs at these sites and presence of podosome-like structures in 
sampling WBCs were visualized in parallel by SEM.  
 
2.5. Recruitment of molecules at sites of ICAM-1 engagement on the endothelial 
plasmalemma. To engage solely ICAM-1 on ECs, we adsorbed anti-ICAM on the 
surface of 4.5 µm diameter polystyrene-latex beads (anti-ICAM beads) as describ d29,66. 
Anti-mannose-6-phosphate receptor (anti-M6PR) beads and anti-VCAM-1 beads s rved 
as controls. Coated beads were incubated for 15 minutes or 30 minutes at 37ºC with 
control HUVECs or HUVECs treated with 5 mM Cdx, 50 µM imipramine, 3 mM 
amiloride, 20 µM 5-(N-ethyl-N-isopropyl)amiloride (EIPA, which inhibits NHE129,70,71), 
0.5 µM wortmannin (to inhibit PI3K), or 10 µM H-7 (to inhibit PKC). Beads that were 
not firmly bound to HUVECs were washed and cells were fixed. Cholesterol and 
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ganglioside GM1 were stained using 50 µg/mL filipin, and polyclonal anti-GM1 followed 
by a Texas Red-labeled secondary antibody, respectively, whereas sphingomyelin was 
visualized by incubating HUVECs with 0.2 µg/mL BODIPY®-sphingomyelin for 16 
hours prior to experiments. Ceramide, ICAM-1, VCAM-1, and M6PR were 
immunostained as noted in Figures, using antibodies that recognize extracellular domains 
of these antigens and do not require cell permeabilization. Immunostainings of ASM and 
NHE1 were performed after permeabilization with 0.2% cold Triton X-100. Anti-ICAM 
on the surface of beads was detected by immunofluorescence using a secondary antibod . 
Beads were first located using phase contrast microscopy. Fluorescence micrographs at 
these positions were then obtained in the z-axis using 0.5 µm steps in SlideBook™ 4.2, 
and images were analyzed using Image-Pro 6.3 (Media Cybernetics, Inc., Bethesda, MD). 
Enrichment of molecules in areas of the EC plasmalemma where beads were bound was 
visualized using pseudocolored fluorescence-intensity surface plots, which ere obtained 
at the bead mid cross-section plane. The mid cross-section of beads is rai ed ~2 µm 
above the plasmalemma level; hence, enrichment of cellular molecules at this section 
shows EC membrane actively engulfing such beads. For semi-quantitative analysis of 
these experiments, fluorescence intensity profiles were averaged from ≥ 32 beads and 
enrichment of a particular molecule was calculated as fold increase (represented as ∆ in 
graphs) in the average intensity at the mid cross-section region of enguled beads over the 
average intensity of ~2 µm surrounding areas where the plasmalemma is not raised 
engulfing beads (“background”). In some instances, binding and/or engulfment of anti-
ICAM beads by ECs was visualized in parallel by SEM. 
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Distribution of ASM was additionally assessed by computing the total number of ASM-
positive vesicles (~100-300 nm fluorescent objects) and those located within 5 µm 
distance around the nucleus (perinuclear). Peripheral ASM was calculated as total − 
perinuclear vesicles.  
 
2.6. CAM-mediated endocytosis of anti-ICAM beads and actin remodeling. For 
endocytosis experiments, TNFα-activated HUVECs, wild-type MLECs or ASM−/− 
MLECs were incubated at 37ºC with 4.5 µm anti-ICAM beads for 30 minutes to allow 
bead binding, followed by washing non-bound beads and incubation at 37ºC for 1 hour to 
allow full endocytosis. Inhibition experiments were performed in the presence of 3 mM 
amiloride, 50 µM imipramine, Na+-depleted ionic solution (138 mM choline chloride, 
5.4 mM KCl, 1 mM CaCl2, 1 mM MgCl2), 0.5 µM wortmannin, or 10 µM H-7. After cell 
fixation, samples were stained using Texas Red-labeled goat anti-mouse IgG, which 
binds to anti-ICAM on non-internalized beads but does not access internaliz d 
counterparts29. Uptake was determined by fluorescence microscopy using Image-Pro 6.3 
by counting total beads (phase contrast) and surface-bound Texas Red-fluor scent 
beads29. 
For actin visualization experiments, TNFα-activated HUVECs were incubated with 4.5 
µm anti-ICAM beads for 30 minutes at 37ºC, followed by washing and fixation, 
permeabilization with 0.2% Triton X-100, and fluorescent labeling of filamentous actin 




2.7. CAM-mediated endocytosis in vivo. Anesthetized C57BL/6, caveolin-1−/− (Jackson 
Laboratory, Bar Harbor, ME) or ASM−/− mice were injected intravenously with 100 nm 
anti-ICAM beads instead of 4.5 µm beads to avoid capillary embolization. Induction of 
vesicular uptake in endothelium was assessed in lungs, to facilitate v sualization due to 
the profuse vasculature in this organ. Mice were perfused 3 h after bead injection and 
lungs were isolated, fixed in 2.5% glutaraldehyde and 0.1 M sodium cacodilate buffer, 
and processed into 80-90 nm-thin resin-embedded sections for transmission electron 
microscopy66. Animal studies adjusted to IACUC regulations. 
 
2.8. Statistics. Data are means ± standard error of the mean (s.e.m.) and statistical 




Chapter 3: Results 
3.1. Effect of disrupting lipid domains or CAM-mediated endocytosis on leukocyte 
transmigration across endothelial cells. We used a model consisting of a confluent 
TNF-α-activated EC monolayer grown on a porous membrane through which IL-2-
activated peripheral-blood lymphocytes (herein called WBCs) can transmigrate, driven 
by presence of chemoattractant SDF-1α in the chamber underneath ECs. Under control 
conditions, 77.7±2.3% WBCs underwent transmigration by 30 minutes, as opposed to 
total lack of transmigration of K562 cells, a non-migratory erythroid leukemia cell line 
used a negative control (Fig. 4A). As expected due to involvement of multiple 
overlapping interactions between WBCs and ECs, TEM was partially (yet significantly) 
inhibited by either blocking ICAM-1-binding integrin LFA-1 on WBCs using anti-LFA-1 
(59.2±11.9% inhibition; Fig. 4A) or by blocking another leukocyte integrin involved in 
leukocyte TEM, VLA-4, which binds to VCAM-1 (41.2±5.6% inhibition; Fig. 4A). Such 
an effect on TEM by blocking LFA-1 or VLA-4 was independent from the WBC capacity 
to transverse the porous membrane in the absence of ECs (Fig. 4B) and, hence, related to 
specific WBC-EC interactions. These data are consistent with previous reports72,73, 





Figure 4. Model to examine transmigration of white blood cells across endothelial monolayers. (A) 
Transport of either peripheral-blood lymphocytes (WBCs, control) or negative control K562 cells across 
activated HUVEC monolayers assessed at 37ºC by counting blood cells  in the bottom chamber underneath 
HUVECs (black bars), 30 minutes after adding blood cells to the upper chamber above HUVECs. 
Transmigration was alternatively performed prior to (c ntrol) or after blocking integrins LFA-1 or VLA-4 
on WBCs using monoclonal antibodies. (B) Transmigrat on of antibody-blocked WBCs in the presence 
(black bars) or absence (white bars) of HUVEC monolayer, as a control. Data are normalized to control 
values, and represent mean and s.e.m. (n ≥ 3 experiments). *, P ≤ 0.001 by Student’s t test. 
 
Using this Transwell system, we observed that WBC transmigration was inhibited by 
Cdx (51.9±4.8% inhibition; Fig. 5A), an agent that depletes cholesterol from cells and 
significantly affects lipid domains, including caveolar sites. However, filipin, a drug that 
binds to cholesterol and can also affect caveolae-mediated pathways on these ECs29, did 
not inhibit WBC transmigration (12.0±7.7% inhibition). Instead, amiloride, which affects 
Na+/H+ exchangers70 and inhibits CAM-mediated endocytosis29, reduced WBC 
transmigration even at a greater extent than Cdx (61.4±3.7% inhibition; Fg. 5A). 
20 
 
Although these inhibitors could affect not only ECs but potentially alsoWBCs, neither 
Cdx nor amiloride impaired the capacity of WBCs to transmigrate across the porous filter 
in the absence of an endothelial monolayer (Fig. 5A).  
 
 
Figure 5. Endothelial binding and transmigration of white blood cells. (A) Transport of activated 
peripheral-blood lymphocytes (WBCs) across activated HUVEC monolayers was assessed at 37ºC by 
counting WBCs in the bottom chamber underneath HUVEC 30 minutes after adding WBCs to the upper 
chamber above HUVECs (black bars). Absence of HUVEC monolayer was a control (white bars). 
Transmigration was performed in the absence (control) o  presence of filipin, methyl-β cyclodextrin (Cdx) 
or amiloride. (B) Binding of activated WBCs (pre-stained with green fluorescent calcein) to activated 
HUVECs growing on glass coverslips was determined after co-incubation for 30 minutes at 37ºC in control 
medium or medium containing filipin, Cdx or amiloride, followed by washing to remove WBCs not firmly 
bound to HUVECs, and fluorescence microscopy (black bars). Data are normalized to control values, and 
represent mean and s.e.m. (n ≥ 3 experiments). *, P ≤ 0.001 by Student’s t test. 
 
Also a as a control, a parallel experiment using WBCs labeled with green-fluorescent 
calcein and ECs growing on coverslips (to avoid confounding results of transmigration) 
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showed no effect of Cdx or amiloride on WBC binding to ECs, as shown after several 
rounds of washing (Fig. 5B). These results agree with previous works suggesting a role 
for lipid domains (and possibly caveolar pathways) on TEM49,57,74. In addition, TEM 
inhibition by amiloride but not filipin corresponds well with the inhibition pattern 
observed for endocytosis of anti-ICAM beads by ECs29, which agrees with a potential 
role for CAM-mediated endocytosis in leukocyte transmigration.  
 
3.2. Lipid domains and CAM-mediated endocytosis in pre-transmigration 
interactions between leukocytes and endothelial cells. A possible contribution of 
CAM-mediated endocytosis to leukocyte TEM could be that of helping to regulate 
dynamic formation of pre-transmigratory surface invaginations and/or engulfing 
structures observed on ECs at the interface with leukocytes that sample the endothelial 
surface in search for sites optimal for transmigration19,48,50,55,56. To explore whether this is 
the case, we used the fluorescence microscopy model described in Figure 5B and looked 
at green-fluorescent WBCs that remained bound to ECs after sev al rounds of washing 
(firm adhesion). WBCs displaying a round morphology were scored as simply “adhered” 
cells, while flat, spread WBCs (which may be arrested, crawling laterally, or undergoing 
transmigration) were scored as “sampling” cells. Presence of WBC podosomes and 
related structures interacting with ECs surface were confirmed in such sampling cells by 
SEM (Fig. 6A, top panel). As shown in Figure 6B, 69.3±2.3% WBCs were sampling the 
EC surface in this model, whereas 30.7 ±10.0 % WBCs were simply adhered to ECs.  
Furthermore, using phase-contrast and fluorescence imaging of the EC surface permitted 
us to better distinguish between sampling WBCs located at EC borders versus those away 
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from borders (herein called EC “body”; see partial engulfment of a WBC by the EC 
plasmalemma at this site; black arrowheads in Figure 7A). These locations were also 
verified by SEM (Fig. 6A, bottom panel). As shown in Figure 6C, sampling WBCs were 
equally distributed between the EC body and the EC border (53.4±4.0% and 46.6±4.0%, 
respectively) and 71.2±3.5% of all WBCs located at the EC body were sampling WBCs 
(Fig. 6D). Although sampling WBCs do not represent those that fully migrate across ECs, 
these results are in well agreement with data published on transmigrating 
leukocytes50,72,73. This suggests that most of these sampling interactions between WBCs 
and ECs can correspond to pre-transmigratory events, half of which may occur 





Figure 6. Model to examine pre-transmigratory interaction of white blood cells and endothelial cells. 
Interaction of activated peripheral-blood lymphocytes (WBCs) with activated HUVECs after incubation for 
30 minutes at 37ºC. (A) Scanning electron microscopy f WBCs interacting with HUVECs. Black 
arrowheads in the top panel show WBC podosomes and related “sampling” structures at the interface with 
HUVECs. Scale bar = 5 µm. The bottom panel shows WBCs located at the EC border (arrow) or away 
from it (EC body; white arrowheads) Nu = Nucleus. Scale bar = 10 µm. (B-D) WBCs pre-stained with 
green fluorescent calcein and observed by fluorescence microscopy on HUVECs. (B) Round WBCs were 
scored as “adhered” cells (white bars) and spread WBCs were scored as “sampling” cells (black bars). (C  
Spatial distribution of sampling WBCs at either theEC body (black bars) or the EC border (white bars). (D  
Fraction of sampling WBCs (black bars) versus adhered WBCs (white bars) within those located at the EC 
body. Data represent mean and s.e.m. (n ≥ 30 WBCs). 
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In accord with our previous set of experiments (Fig. 5), Cdx and mainly miloride, but 
not filipin, reduced the number sampling WBCs (80.5±6.8%, 63.8±7.3% and 108.7±8.6% 
of control, respectively; Fig. 7B). In particular, Cdx and amiloride shifted the number of 
sampling WBCs at the EC border over the EC body (124.9±17.1% over 78.3±14.9% for 
Cdx and 139.6±34.1% over 65.5±29.7% for amiloride; Fig. 7C). Regarding only WBCs 
located at the EC body, Cdx and amiloride decreased sampling WBCs (71.5±14.6% and 
56.0±27.5% of control) and increased the number of WBCs simply adhered 
(170.5±36.2% and 209.1±68.1% of control; Fig. 7D). Hence, this set of experiments 
suggests a main role for lipid domains and CAM-mediated endocytosis at the interface 




Figure 7. Pre-transmigratory interaction of white blood cells and endothelial cells. Interaction of 
activated peripheral-blood lymphocytes (WBCs, pre-stained with green fluorescent calcein) with activated 
HUVECs growing on glass coverslips was determined after co-incubation for 30 minutes at 37ºC in control 
medium or medium containing filipin, methyl-β-cyclodextrin (Cdx) or amiloride. WBCs not firmly adhered 
to HUVECs were washed, followed by fixation, immunostaining of ICAM-1 in blue, and analysis by 
fluorescence microscopy. (A) The image shows an example of flat spread WBCs scored as “sampling” 
(arrowheads, black for EC body and white for EC border), compared to rounded WBCs scored as simply 
“adhered” (arrow). Cell borders are indicated by semi-transparent dashed lines. Scale bar = 10 µm. (B) 
Percent of sampling WBCs on HUVECs (black bars). (C Spatial distribution of sampling WBCs, scored as 
occurring at either the EC body (black bars) or the EC border (white bars). (D) Fraction of sampling WBCs 
(black bars) versus simply adhered WBCs (white bars) within those located at the EC body. Data are 
normalized to control values (horizontal dashed lines) and represent mean and s.e.m. (n ≥ 30 WBCs). *, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001 by Student’s t test.  
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3.3. Association of lipid domains and the sphingomyelin/ceramide pathway with 
endothelial docking structures induced by ICAM-1 engagement. Endothelial 
engulfment of leukocytes at lipid raft-like, ICAM-1-rich docking structures occurs in 
association with leukocyte adhesion to the endothelium and TEM, including those 
processes that involve transcellular pores19,48,55,56. However, experiments using 
leukocytes involve engagement of multiple adhesion molecules on the endothelial 
plasmalemma. Also, inhibitors present in the cell medium during experiments may affect 
both EC and leukocyte counterparts. Therefore, to focus on events that occur on ECs and 
to better correlate engagement of ICAM-1 with lipid domains at the EC surface, we used 
polymer beads coated with multiple copies of an antibody against ICAM-1 (anti-ICAM 
beads). This reductionist, yet valuable, tool has been previously used for in ucing on ECs 
processes similar to those elicited by leukocyte adhesion33,56,73 and has been extensively 
used in the context of the CAM-mediated pathway29,64,66,71.  
Fluorescence microscopy at different focal planes on the z-axis (Fig. 8A) showed that, 
within 15 minutes incubation, anti-ICAM beads (immunostained in green FITC) bound to 
ECs and were engulfed by ICAM-1-enriched membrane protrusions (immunostained in 
Texas Red). SEM (Fig. 8B) confirmed that bead engulfment areas w re morphologically 
similar to endothelial docking structures observed during leukocyte TEM48,55,74. Also 
validating this model, analysis of fluorescence intensity at the bead mid cross-section 
region showed that sites of bead engulfment by ICAM-1 engagement were enriched in 





Figure 8. Induction of endothelial docking-like structures upon ICAM-1 engagement by anti-ICAM 
beads. Activated HUVECs were incubated with anti-ICAM beads for 15 minutes at 37ºC to engage ICAM-
1 on endothelial cells (ECs), followed by washing and fixation. (A) Fluorescence micrographs were 
obtained at different planes along the z-axis (i to v, where iv is closest to the plasma membrane), after 
staining anti-ICAM on the surface of beads using a FITC-labeled secondary antibody and ICAM-1 on the 
EC surface using a Texas Red-labeled antibody. Scale bar = 5 µm. (B) Scanning electron micrograph of an 
anti-ICAM bead being engulfed (black arrows) by an EC. Scale bar = 2.5 µm. (C) Fluorescence 
immunostaining of tetraspanin CD9 in ECs, at regions f binding of anti-ICAM beads. Left panel shows a 
micrograph showing CD9 enrichment as ring-like structures (white arrows). Scale bar = 10 µm. Right panel 
shows CD9 fluorescence intensity plot at the mid cross-section plane of anti-ICAM beads. Data represent 




Then, using non-fluorescent beads to minimize optical interference whil fluorescently 
labeling lipids of the plasma membrane, we observed that typical lipid raft-domain 
components such as cholesterol, sphingomyelin and ganglioside GM1 were enriched in 
areas of engulfment of anti-ICAM beads that mimic endothelial docking structures (ring-
shaped fluorescent regions in Figure 9A). Semi-quantitative analysis (see Materials and 
Methods) revealed that the fluorescence intensity of the labeled lipids was increased by 
1.6±0.04-fold, 3.1±0.1-fold, and 4.7±0.4-fold, for cholesterol, sphingomyelin and 
ganglioside GM1, respectively, in regions of bead engulfment by ICAM-1 engagement 
versus adjacent “background” areas (Fig. 10A). At the concentration used, neither Cdx 
treatment to chelate cholesterol (confirmed in Figures 9B and 10B, top panels) nor 
amiloride treatment to inhibit CAM-mediated pathway affected firm binding of anti-
ICAM beads to ECs (compare phase-contrast pictures in Figures 9A, 9B, and 11 showing 
beads bound to ECs after several rounds of washes). However, both Cdx and amiloride 
decreased bead engulfment, as reflected by reduced ICAM-1 signal at the middle plane 
around beads (41.7% and 29.2% decrease, respectively; Figs 9B, 10B, and 11). These 
results correlate well with our findings showing that disruption of lipid domains and 
CAM-mediated pathway affect both WBC-EC pre-transmigration interac ions and WBC 




Figure 9. Recruitment of molecules at sites of endothelial ICAM-1 engagement by anti-ICAM beads. 
Activated HUVECs were incubated with anti-ICAM beads for 15 minutes at 37ºC to engage ICAM-1 on 
endothelial cells (ECs), followed by washing and fixat on. (A) Cholesterol (top panel), sphingomyelin 
(middle panel) or ganglioside GM1 (bottom panel) were stained using fluorescent blue filipin, green 
BODIPY-sphingomyelin, or anti-GM1 and a Texas Red-labeled secondary antibody, respectively. (B) 
Effect of methyl-β-cyclodextrin (Cdx) on enrichment of cholesterol labeled with blue filipin (top panel) or 
ICAM-1 immunostained with a Texas Red-labeled antibody (middle and bottom panels) in regions of anti-
ICAM bead binding. (C) Immunostaining of ceramide using a FITC-labeled antibody in regions of anti-
ICAM-bead binding in control (top left panel), imipramine-treated (bottom left panel), and EIPA-treated 
(top right panel) cells. The bottom right panel shows ceramide fluorescence intensity plots at the mid cross-
section plane of anti-ICAM beads bound to ECs under control (circles), imipramine (triangles), or EIPA 
(squares) conditions. In all cases, left sub-panels show fluorescence micrographs and phase-contrast inse s 
of bound beads. Right sub-panels show pseudocolored fluorescence intensity reconstructions of molecules 
in the EC plasmalemma at areas of bound beads, which are indicated by arrows on their respective left sub-





Figure 10. Quantification of enrichment of molecules at the endothelial plasmalemma in areas of 
ICAM-1 engagement by anti-ICAM beads. Activated HUVECs were incubated with anti-ICAM beads 
for 15 minutes at 37ºC to engage ICAM-1 on endothelial cells (ECs), followed by washing and fixation. 
(A) Cholesterol (upper panel), sphingomyelin (middle panel) or ganglioside GM1 (bottom panel), were 
stained using fluorescent blue filipin, green BODIPY-sphingomyelin, or anti-GM1 and a Texas Red-
conjugated secondary antibody, respectively. (B) Effect of methyl-β-cyclodextrin (Cdx) on enrichment of 
cholesterol labeled with blue filipin (upper panel) or ICAM-1 immunostained with a Texas Red-labeled 
antibody (middle and bottom panels) in regions of anti-ICAM-bead binding. (C) Effect of EIPA and 
imipramine on ICAM-1 immunostained with a Texas Red-conjugated antibody in regions of anti-ICAM-
bead binding. In all cases, graphs show fluorescence intensity plots at the mid cross-section plane of anti-
ICAM beads bound on ECs, and enrichment of molecules in these engulfment areas compared to adjacent 
areas of the endothelial plasmalemma (∆, which indicates fold increase). Data represent mean and s.e.m. (n 
≥ 65 beads). 
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Furthermore, since hydrolysis of sphingomyelin into ceramide contributes to formation of 
large lipid domains, and this pathway is associated with modulation of the plasmalemma 
plasticity and cytoskeletal signaling75-78, features required during leukocyte TEM, we 
tested for ceramide at regions of ICAM-1 engagement by anti-ICAM beads. As shown in 
Figure 9C, ceramide also increased over adjacent areas at these regions (3.5±0.01-fold), 
which was impaired by EIPA (35.6% decrease; Fig. 9C), an amiloride derivative that 
more specifically inhibits NHE1 involved in CAM-mediated endocytosis29,71. EIPA also 
reduced bead engulfment, causing reduced ICAM-1 signal around beads (42.7% 
decrease; Fig. 10C). This suggests for the first time that NHE1 may connect the CAM-
mediated pathway to sphingomyelin/ceramide signaling. 
 
Figure 11. Effect of amiloride on the formation of ICAM-1-rich endothelial docking-like structures 
by anti-ICAM beads. Fluorescence micrographs show activated HUVECs incubated for 15 minutes at 
37ºC with anti-ICAM beads to engage ICAM-1 on endothelial cells (ECs), under control conditions (top 
panel) or in the presence of amiloride (bottom panel). Cells were washed and fixed, ICAM-1 was 
immunostained using a Texas Red-labeled antibody, and s mples were observed by phase-contrast (left 
panels) and fluorescence (right panels) microscopy. Presence or absence of bead engulfment is marked with 
arrows or arrowheads, respectively. Scale bar = 10 µm. 
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3.4. Recruitment of acid sphingomyelinase to endothelial docking-like structures. 
Contribution of the sphingomyelin/ceramide pathway to formation and/or maintenance of 
endothelial docking sites and structures at the interface between transmigrating 
leukocytes and ECs may require sphingomyelinase activity. Given that NHE1 provides 
acidification at the extracellular side of the plasmalemma79, we inferred that ASM, a 
lysosomal enzyme that can be secreted80, could be involved in ceramide generation at 
these regions. In accord with this, imipramine, a drug that inhibits ASM, impaired 
ceramide enrichment in areas of bead engulfment associated to ICAM-1 engagement 
(23.6% decrease; Fig. 9C), implicating for the first time ASM in ICAM-1-driven 
formation of endothelial docking-like structures. 
In addition, immunofluorescence of ASM in ECs showed that, in absence of ICAM-1 
engagement by anti-ICAM beads, most ASM located to vesicular compart ents in the 
perinuclear region of cells (41.8±4.7 vesicles/cell), while few ASM-positive vesicles 
were found outside the perinuclear area (23.7± .3 vesicles/cell; Fig. 12). ICAM-1 
engagement by anti-ICAM beads lead to appearance of ASM-positive vesicles at the cell 
periphery (1.7-fold and 2.3-fold increase at 15 minutes and 30 minutes, respectively), and 
anti-ICAM bead engulfment areas became enriched in ASM (Fig. 13A). As negative 
controls for ICAM-1 specificity and optical artifacts, beads coated with antibodies to 
VCAM-1, also involved in leukocyte TEM, or M6PR, involved in clathrin-mediated 
transport of ASM81, did not elicit ASM recruitment despite binding to ECs (Fig. 13A). 
Anti-M6PR beads induced recruitment neither of ICAM-1 nor NHE1, but recruit d 
clathrin heavy chain (Fig. 14), validating this model. Importantly, areas of bead 
engulfment mediated by ICAM-1 engagement (Fig. 13B) revealed that ASM colocalized 
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well with both ICAM-1 and NHE1 (85.1±2.9% and 85.3±3.4% of total beads were 
positive for the two molecules, respectively). At high image magnification, ASM 




Figure 12. Intracellular redistribution of endothelial acid sphingomyelinase upon ICAM-1 
engagement by anti-ICAM beads. Activated HUVECs were incubated in the absence (top panel) or 
presence (bottom panel) of anti-ICAM beads for 30 minutes at 37ºC. Cells were fixed and permeabilized, 
and ASM was stained with a Texas Red-labeled secondary antibody. Arrowheads mark ASM at the 
perinuclear region of cells. Arrows mark ASM at thecell periphery. Dashed lines mark the cell borders, as 




Figure 13. Plasmalemma distribution of endothelial acid sphingomyelinase upon ICAM-1 
engagement by anti-ICAM beads. Activated HUVECs were incubated with anti-ICAM, anti-VCAM or 
anti-M6PR beads for 15 minutes at 37ºC to engage these molecules on endothelial cells (ECs), followed by 
washing and fixation. (A) Fluorescence immunostaining of ASM (bottom panels) in regions of respective 
bead binding (phase-contrast, top panels). Scale bar = 10 µm. (B) Fluorescence microscopy showing 
immunostaining of ASM (green), and ICAM-1 (red, top four panels) or NHE1 (red, bottom four panels). 
Boxes indicate the respective beads and bead regions selected for enlargement in 4X and 16X panels, as 




Figure 14. Recruitment of molecules at sites of anti-M6PR bead binding. Activated HUVECs were 
incubated with anti-mannose-6-phosphate receptor (M6PR) beads for 15 minutes at 37ºC to engage M6PR 
on endothelial cells (ECs), followed by washing and fixation. Phase contrast (left panels) and fluorescence 
micrographs (right panels) were obtained after immunostaining ICAM-1 (top), NHE1 (middle), or clathrin 
heavy chain (bottom) with Texas Red. Arrowheads indicate lack of enrichment of the corresponding 
marker around beads. Arrows indicate enrichment of the corresponding marker around beads. Scale bar = 
10 µm. 
 
3.5. Effect of impairing acid sphingomyelinase on CAM-mediated endocytosis and 
associated cytoskeletal rearrangement. Ceramide production by ASM at sites of 
ICAM-1 engagement where NHE1 may acidify the milieu could provide plasmalemma 
plasticity and likely activate cytoskeleton-associated signaling75-78 required by endothelial 
docking-like structures involved in engulfment of micron-sized objects and pre-
transmigratory structures at the interaction with leukocytes, to which we believe CAM-
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mediated endocytosis may contribute. To explore this aspect, we track d internalization 
of anti-ICAM beads by ECs using a microscopy technique extensively employed in our 
previous works, which differentially distinguishes surface-bound beads ( ccessible to a 
fluorescently-labeled secondary antibody that marks anti-ICAM on beads) versus beads 
residing within EC compartments (non-accessible to said secondary antibody)29.  
In agreement with our hypothesis, inhibition of ASM with imipramine a d Na+ depletion 
(to impair Na+/H+ transport and extracellular acidification) decreased endocytosis of anti-
ICAM beads by ECs (from ~38% to 93% reduction; Table 2). This is similar to the 
previously observed inhibition of CAM-mediated endocytosis by affecting NHE1 with 
amiloride, and opposed to lack of an effect by treatment with filipin (~86% reduction 
versus ~7% increase, respectively; Table 2). ASM involvement was also confirmed in 
genetically modified models, to circumvent specificity concerns of pharmacological 
inhibitors. As shown in Table 2, using ECs isolated from wild-type versus ASM−/− mice, 
we observed that lack of ASM reduced endocytosis of anti-ICAM beads (75% reduction 
compared to ECs isolated from wild-type mice; Table 2). 
Table 2. Inhibition of CAM-mediated endocytosis in the context of acid sphingomyelinase function. 
 Internalization (%) 
HUVECs  
   Control 100.0±7.6 
   Amiloride 13.8±3.3** 
   Imipramine 61.9±6.7** 
   Na+ depletion 7.4±2.5** 
   Filipin 107.2±1.5 
MLECs  
   Control 100.0±25.4 
   ASM−/− 25.4±10.5* 
Values are normalized to controls. 
* is P ≤ 0.05 and ** is P ≤ 0.001. 
n ≥ 10 micrographs from 2 replicates. 
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This was further confirmed in vivo by injecting anti-ICAM beads intravenously in wild-
type, caveolin-1−/− or ASM−/− mice, followed by isolation of lungs 3 h after injection and 
visualization by transmission electron microscopy. As in cell cultures, engulfment 
leading to endocytosis of anti-ICAM beads by ECs was inhibited in ASM−/− mice but not 
in caveolin-1-/- mice (12.2% and 92.8% of wild-type mice; Fig. 15). In ASM−/− mice, 
fewer membrane invaginations were detected in association with anti-ICAM beads (Fig. 
15i,iv,vii), and the beads internalized in these mice were individually located within 
vesicles (Fig. 15ix), in contrast to large vesicular structures containing multiple beads 
observed in wild-type and caveolin-1−/− mice (Fig. 15iii,vi). 
 
Figure 15. CAM-mediated endocytosis in vivo. Wild-type (i-iii), caveolin-1−/− (iv-vi), or ASM−/− (vii-ix) 
mice were injected intravenously under anesthesia with anti-ICAM beads and after 3 h lungs were isolated, 
perfused, and processed for transmission electron microscopy. Arrows indicate beads being internalized in 
endothelial invaginations. Arrowheads indicate beads fully internalized in intracellular vesicles. EC = 
endothelial cell, VL = (blood) vessel lumen. Scale bars = 200 nm or 500 nm, as indicated. The number of 
beads internalized within ECs was quantified from the micrographs. Data represent mean and s.e.m. (n ≥ 13 
micrographs). *, P ≤ 0.05 by Student’s t test.  
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Along with CAM-mediated endocytosis, imipramine treatment to inhibit ASM also 
disrupted formation of actin stress fibers that are induced by ICAM-1 engagement on 
ECs using anti-ICAM beads. In particular, formation of stress fibers within the cell body 
(versus cell edges) seemed most affected (Fig. 16A). This finding implies that ASM 
recruitment to sites of ICAM-1 engagement occurs prior to cytskeletal rearrangement. 
Confirming this, inhibition of PKC, which has been reported to regulate formation of 
actin stress fibers by CAM-mediated endocytosis, did not affect ASM recruitment at 
ICAM-1 binding sites, but did inhibit uptake of anti-ICAM beads (Fig. 16B) and both 
these events were independent of PI3K signaling (Fig. 16B).  
Figure 16. Acid sphingomyelinase and cytoskeleton-associated signaling upon ICAM-1 engagement. 
Activated HUVECs were incubated with anti-
ICAM beads for 15 minutes (except for black 
bars in B, see below) at 37ºC to engage ICAM-1 
on endothelial cells (ECs) under control 
conditions or in the presence of imipramine, H-
7, or wortmannin, as indicated. (A) Top panels 
show phase-contrast micrographs of bound 
beads, with dashed lines indicating cell borders 
as seen through phase-contrast. Bottom panels 
show actin staining with Alexa Fluor 594-
labeled phalloidin of control versus imipramine-
treated cells. Arrows show disruption of actin 
stress fibers in the EC body. Arrowheads show 
actin stress fibers near cell edges. Scale bar = 20 
µm. (B) Black bars: ASM was stained as in 
Figure 13 and enrichment was quantified by 
generating fluorescence intensity plots at the 
mid cross-section plane of anti-ICAM beads as 
in Figure 9. Data are normalized to control (n ≥ 
75 beads). White bars: Activated HUVECs were 
incubated with anti-ICAM beads for 1 hour at 
37ºC to allow for internalization. Non-bound 
beads were washed, cells were fixed, and 
surface-bound beads were immunostained in 
Texas Red. Total amount of beads was 
quantified from phase-contrast images and 
surface-bound non-internalized beads were 
quantified by fluorescence microscopy to 
calculate the percent of internalized beads. Data 
represent mean and s.e.m. (n ≥ 20 cells). *, P ≤ 




3.6. Acid sphingomyelinase in pre-transmigration interactions between leukocytes 
and endothelial cells. The results above, linking CAM-mediated endocytosis to ASM 
suggest that ASM may be involved in regulating leukocyte-EC interactions at pre-
transmigratory sites. If this is the case, ASM must appear at such areas of leukocyte 
migration across ECs and its inhibition should affect said interactions. Confirming this, 
fluorescence microscopy revealed enrichment of ASM (immunostained in Texas Red, 
marked by arrows in Figure 17A) at the interface between ECs and sampling WBCs 
(stained with green calcein). This is similar to our observations of endothelial docking-
like structures formed upon sole engagement of ICAM-1 by anti-ICAM beads (Fig. 13). 
Imipramine treatment to inhibit ASM led to a decrease in sampling WBCs (46.6±7.6% of 
control; Fig. 17B), without affecting WBC binding to ECs (108.0±18.6% of control). As 
shown for Cdx and amiloride in Figure 7, ASM inhibition with imipramine decreased the 
number of WBCs sampling the EC body below that of WBCs sampling the EC border 
(Fig. 17C). From the WBC population located within the EC body, there was a decrease 
in sampling WBCs and an increase in WBCs simply adhered (Fig. 17D). These results 
suggest that ASM activity linked to ICAM-1-engagement may be involved in the 
regulation of pre-transmigratory sites at the EC plasmalemma, and that this may be of 




Figure 17. Acid sphingomyelinase enrichment at the interface between white blood cells and 
endothelial cells and its role in WBC sampling. Interaction of activated peripheral-blood lymphocytes 
(WBCs, pre-stained with green fluorescent calcein) with activated HUVECs growing on glass coverslips, 
determined after co-incubation for 30 minutes at 37ºC in control medium or medium containing 
imipramine, and analyzed by fluorescence microscopy as described for Figure 7. (A) Phase contrast (top 
left panel) and Texas Red immunostaining of ASM (top right and bottom panels) at the WBC-HUVEC 
interface in control conditions. ASM enrichment at these sites is marked by black arrows. Nu = nucleus. 
Scale bars = 10 µm in top right panel, and 2 µm in bottom panel. (B) Percent of sampling WBCs, calcul ted 
from WBCs firmly bound to HUVECs (black bars). (C) Spatial distribution of sampling WBCs, scored as 
occurring at either the EC body (black bar) or the EC border (white bar). (D) Fraction of sampling WBCs 
(black bar) versus simply adhered WBCs (white bar) within those located at the EC body. Data are 
normalized to control values (horizontal dashed lines), and represent mean and s.e.m. (n ≥ 100 WBCs). *, P 




Chapter 4: Discussion 
CAM-mediated endocytosis is an NHE1/dynamin-dependent, clathrin- and cveolae-
independent endocytic pathway induced by engagement of ICAM-1 on ECs (e.g., by 
means of anti-ICAM conjugates and polymer beads)29,66,71. It results in massive 
cytoskeletal rearrangement with formation of actin stress fibers and endocytic vesicles 
between ~200 nm and several micrometers in diameter, which occurs without disruption 
of the EC junctions and seems involved in ICAM-1 recycling29,66,71,82. The results 
described in this work support a potential contribution of this pathway, along with 
sphingomyelin/ceramide signaling, to regulation of plasmalemma structures on ECs 
associated with leukocyte transmigration during inflammation. 
It is known that, in addition to leukocytes35,48,83,84, the endothelium plays an active role in 
defining the transmigration route (i.e., paracellular versus transcellular) during leukocyte 
TEM19,48,49,55,56,85. ECs extend dynamic actin-anchored ICAM-1-rich protrusions that 
engulf leukocytes (transmigratory cups or docking structures), providing tractive force 
for transmigration19,48,55. In the case of transcellular TEM, endothelial endocytic vesicles 
that form at these sites coalesce generating a transcellular pore through which leukocytes 
transmigrate48,53. The fact that ICAM-1, compared to other adhesion molecules, plays a 
key role in transcellular TEM19,34,49,50,55 supports our findings that endocytic events 
induced by ICAM-1 engagement (CAM-mediated pathway) are involved, at least to some 
extent, in the regulation of this process. 
During CAM-mediated endocytosis, ICAM-1 interacts with the Na+/H+ exchanger 
NHE129,71. This exchanger, which is known to be involved in cytoskeletal 
rearrangement86,87, acts as a crosslinker of actin filaments to the cytosolic domain of 
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ICAM-171. The ion exchange activity of NHE1 also regulates the elasticity of the 
endothelial apical surface88, in agreement with high permissibility of CAM-mediated 
endocytosis for engulfment and uptake of large micron-sized objects in vitro and in 
vivo66. Presumably, such deformability properties of CAM-mediated endocytosis would 
suitably adapt for formation of large endothelial docking structures, th  wide range of 
sizes exhibited by the invasive podosomes and related structures that leukocytes extend 
into ECs during TEM, and possibly formation of transcellular pores observed in 
transcellular TEM48,53.  
Also in the context of CAM-mediated endocytosis and leukocyte TEM, diffusion of 
molecules in the plasmalemma must be temporarily reduced in areas of binding to 
ICAM-1, to permit formation of engagement and signaling platforms and to anchor the 
cytoskeleton, which has been recently observed33. The level of deformability required to 
engulf large objects and cells by endothelial docking structures progressing into 
transmigration pores must also relate to a particular lipid composition of the 
plasmalemma. Indeed, leukocyte TEM has been linked to cholesterol-, sphingomyelin-, 
and/or ganglioside-rich areas in lipid rafts and tetraspanin domains49,57,74. As shown in 
this work, such domains seem to be related also to the CAM-mediated p hway and are 
associated to induction of sphingomyelin/ceramide signaling upon ICAM-1 engagement 
at the EC plasmalemma.  
The enrichment in ceramide at endothelial docking-like structures induced by ICAM-1 
engagement is likely to impact the molecular and biophysical features of these areas of 
the plasma membrane. As observed in other systems, ceramide confers particular 
properties to the membrane environment depending on the ratio of raft components89, 
43 
 
e.g., it can promote the formation of large lipid domains76,77 or displace lipid domain 
constituents to affect membrane function75. Ceramide production by ASM at the outer 
leaflet of the plasma membrane modifies its curvature and results in vesiculization77,78,90, 
as well as cytoskeletal rearrangement75,91, supporting similar observations in this work. 
These events downstream of the sphingomyelin/ceramide pathway could contribute to 
formation of large micron-sized vesicles, as observed in CAM-mediated endocytosis 
(Table 2)29,66. In addition, ceramide production by (acid) sphingomyelinase is known t 
be associated with vesicular fusion92,93, which is in accord with our results showing the 
accumulation of several anti-ICAM beads within the same intracellular compartment in 
wild-type, but not ASM–/– mouse endothelium (Fig. 15). 
Supporting the link between CAM-mediated endocytosis, ASM, and the formati n of 
dynamic, fusing vesicles, unpublished work by other members of our grp shows that 
ICAM-1 multivalent engagement using streptavidin-linked biotinylated anti-ICAM 
induces the formation of structures that resemble transcellular pores (Fig. 18). This is 
seen when anti-ICAM present on the cell surface versus internalized within endocytic 
vesicles is differentially immunostained before and after cell p rmeabilization using 
secondary antibodies conjugated to Texas Red or green FITC, respectively. In certain 
instances, regions of the endothelial membrane show internal, but not surface staining 
(Fig. 18A), indicating localized regions of endocytosis. Here, anti-ICAM-positive 
vesicles resulting from such endocytosis (~200-300 nm diameter; whitearrowhead in 
Figure 18A) appear to be all grouped in bundles forming large structures (~10 µm 
diameter; arrows in Figure 18A). Numerous vesicles within these platforms appear to 
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fuse into larger vesicles (black arrowhead in Figure 18A), which resemble the 
preliminary steps into formation of a transcellular pore53. 
 
Figure 18. Induction of transcellular pore-like structures by ICAM-1 engagement. Activated HUVECs 
were incubated in the presence of anti-ICAM biotin-streptavidin conjugate (A), anti-ICAM beads (B), or 
green calcein-stained peripheral-blood lymphocytes (WBCs, C). (A) ICAM-1 double-stained on endothelial 
cells (ECs) with a Texas Red-labeled secondary antibody prior to permeabilization (cell surface), and a 
FITC-labeled secondary antibody post-permeabilization (internalized). Top panel shows phase contrast, 
where box indicates the location of a transcellular pore-like structure (black arrows) observed by 
fluorescence microscopy (middle panel). White arrowhead shows vesicles of 200-300 nm in diameter. 
Black arrowhead shows larger micrometer-size vesicl resulting from fusion. (B) Individual frames 
obtained from time-lapse phase-contrast microscopy (time is indicated in minutes (’) and seconds (’’)) 
showing formation of a transcellular pore-like struc ure underneath a bead bound to cell surface closeto the 
nuclear region. Black arrows mark the original positi n of the anti-ICAM bead. (C) Green calcein-stained 
WBC found transmigrating through a transcellular poe (white arrow) formed on an EC whose surface was 
immunostained in blue with anti-ICAM. Nu = Nucleus. Scale bars = 10 µm. 
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Supporting these notions, dynamic time-lapse imaging using phase-contrast as shown in 
Figure 18B, allows to observe the sequential formation of a pore-like structure 
underneath a bound anti-ICAM bead, with the particle disappearing from the focal plane 
into the opening (Fig. 18B). This opening closely resembles genuine tra smigration pores 
that form across ECs at sites of transcellular TEM of WBCs (Fig. 18C), suggesting that 
CAM-mediated pathway may contribute to this process. 
 Of note, such coalescence of CAM-derived vesicles into pore-like structures is difficult 
to track in time. The appearance of these structures often occurs oncomitantly in most 
ECs in a given sample, yet this occurs at different time points (be ween 15 minutes and 1 
hour tested) in independent experiments. This emphasizes the highly dynamic and 
transient nature of these events, which are likely to be subject to additional regulatory 
elements in more physiological conditions involving multiple leukocyte-EC interactions, 
perhaps also in concert with caveolar pathways. In any case, formation of transcellular 
pore-like structures from vesicles induced via CAM-mediated endocytosis is in 
agreement with our findings showing that this pathway operates through the 
sphingomyelin/ceramide pathway and may contribute to the overall process of 
transcellular TEM. 
Also consistent with our findings, ECs constitutively secrete ASM, whose activity 
increases upon exposure to certain inflammatory cytokines80, making ASM catalysis 
available at the plasmalemma. As found in this work, ICAM-1 engagement at the EC 
surface leads to ASM redistribution from perinuclear to non-perinuclear areas in ECs, 
accompanied by enrichment of this enzyme in regions of ICAM-1 engagement by anti-
ICAM beads and WBCs (Figs 14, 17). It is known that lysosomes carrying ASM can be 
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exocytosed90, a possible mechanistic explanation for the redistribution and presence of 
this enzyme at the plasmalemma in our study. Secretion of lysosomal ASM is mediated 
by increase in intracellular Ca2+ (ref. 94), a phenomenon also known to be involved in 
CAM-mediated endocytosis upon ICAM-1 engagement71, additionally associated to 
leukocyte interaction with ECs61. 
Ceramide production by sphingomyelinases has also been tied to the inflammatory 
response under a variety of scenarios, including increased rolling and binding of 
leukocytes to brain endothelium95. Other work indicates that leukocyte influx into 
alveolar space is decreased in ASM−/− mice96, and metabolic imbalances causing high 
levels of ceramide can lead to higher leukocyte levels in tissue97. Our data showing 
redistribution of ASM to endothelial docking-like structures and the interfac  between 
WBCs and ECs, along with enrichment of ceramide in these regions, are consistent with 
this literature.  
Given that ICAM-1 interacts with NHE1 upon ICAM-1 engagement71, and due to the 
directionality of NHE1 ion exchange (Na+ influx / H+ efflux)79,86, it is expected that ion 
transport activity of NHE1 will locally acidify ICAM-1 engagement regions, creating a 
confined acidic microenvironment. A similar function of NHE1 has been shown in the 
context of certain pH-sensitive enzymes79. Particularly, inhibition of NHE1 with 
cariporide ameliorates the cisplatin-induced ceramide generation by ASM98. Secreted 
ASM, whose pKa is acidic
80, should only be able to efficiently hydrolyze sphingomyelin 
into ceramide at NHE1-enriched, ICAM-1 engagement regions. This provides a suitable 
explanation on how an acidic enzyme can carry activity at the othrwise neutral 
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extracellular environment and may also contribute to understanding the means by which 
ECs regulate ceramide production with spatial precision.  
Altogether, the data obtained in this work suggest a model (Fig. 19) by which 
engagement of ICAM-1 in lipid domains enriched in sphingomyelin induces secretion of 
ASM from intracellular compartments to these areas of the endothelial plasma 
membrane. At these sites, engaged ICAM-1 forms a complex with NHE1, which results 
in local acidification, sphingomyelin hydrolysis by secreted ASM, and local production 
of ceramide. This signal leads to actin polymerization and cytoskeleton remodeling, 
stabilizes the engagement platform by restricting molecular diffusion and providing 
cytoskeletal anchorage, regulates membrane deformability, and favors dynamic formation 
of CAM-mediated endocytic vesicles, which occurs at sites of leukocyte-podosome 
sampling in search from sites suitable for transcellular TEM. Finally, vesicular fusion 
mediated through sphingomyelin/ceramide signaling at this interface contributes to 
transmigration pores. 
 
Figure 19. Model for the contribution of CAM-mediated endocytosis and the 
sphingomyelin/ceramide pathway to leukocyte transcellular transmigration. (a.) Binding of leukocytes 
to ICAM-1 located at cholesterol and sphingomyelin- (SM)-rich areas of the EC plasmalemma recruits 
NHE1 to binding sites and (b.) serves as a signal for redistribution of ASM from intracellular compartments 
to the EC surface. H+ extrusion by NHE1 at sites of ICAM-1 engagement creates a pH microenvironment 
optimal for ASM activity, where SM is hydrolyzed to ceramide (Cer). (c.) Ceramide production induces th  
rearrangement of the actin cytoskeleton and favors negative curvature of the membrane, resulting in 
formation of endothelial docking structures and endocytic vesicles at these sites. (d.) Ceramide-rich 




Chapter 5: Conclusions and future directions 
In this study, we found that ASM is involved in CAM-mediated endocytosis, and this 
pathway contributes to leukocyte transmigration, likely through the transcellular route by 
formation of endothelial docking structures and transcellular pores. Until recent years, the 
events regulating the route of leukocyte TEM (transcellular versus paracellular) have 
been difficult to elucidate. Our findings will be further tested in order to confirm that 
CAM-mediated endocytosis contributes particularly to leukocyte transcellular migration. 
This will involve the use a larger array of tools such as knockout and knockdown 
leukocytes and ECs, along anti-ICAM beads of different sizes and targeting different 
epitopes of ICAM-1, and animal models. As a key component of the inflammatory 
response, leukocyte TEM is associated with multiple immune diseases. For instance, 
paracellular migration, which involves the disassembly of cell-cell junctions99,100, may 
lead, under pathological conditions, to excessive vascular permeability nd leakage of 
plasma into tissue101,102. Potentiation of the transcellular route might allow for therapeutic 
intervention during pathological states or conditions where this is the case. Further, it has 
been recently shown that leukocytes can migrate transcellularly ac oss fibroblasts103. 
Thus, it will be interesting to extend studies on the contribution of CAM-mediated 
endocytosis to transcellular migration across cell types other than ECs, and determine if 
there exist any physiological implications to these activities. Indeed, we have seen CAM-
mediated endocytosis occur in cell types other than ECs. 
The found contribution by ASM to CAM-mediated endocytosis in this work reinforces 
the emerging role of this enzyme during signaling and inflammatory events, which 
should be further studied in order to understand how the multiple functions ascribed to 
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ASM80,104 are regulated. Ceramide production at the plasma membrane elicits diverse 
signaling events75,80,91,105-107, and has been linked to the entry of pathogens into cells108-
110. Vesicle formation by ceramide appears to be independent of other cellular factors78, 
and thus, it might be possible to use sphingomyelinases to drive endocytosis of objects 
under a variety of scenarios. This might constitute a new tool in the modulation of 
controlled therapeutic delivery into cells, and future work in our lab will study the 
possibility of using ceramide to enhance the entry of large objects into cells, besides 
those that elicit CAM-mediated uptake. 
However, the role of ceramide during CAM-mediated endocytosis goesbeyond the 
formation of vesicles, as our findings suggest that ceramide is also involved in formation 
of docking structures, and rearrangement of the actin cytoskeleton into stress fibers. It 
will be interesting to understand the mechanisms through which ceramide achieves these 
outcomes during leukocyte transmigration and other phenomena that depend on 
endocytosis and cytoskeletal rearrangement. For instance, certain groups have 
hypothesized that multivalent engagement of ICAM-1 induces formation of actin stress 
fibers by displacement of ezrin/moesin from the cytosolic tail of ICAM-1, followed by 
recruitment of cortactin111. Indeed, ceramide production at the plasma membrane causes 
dephosphorylation of ezrin and its displacement to the cytosol75. Confirming and 
elucidating mechanistic steps such as this one will be crucial for full understanding of the 
links between the sphingomyelin/ceramide pathway, CAM-mediated endocytosis, and 
leukocyte TEM. 
Finally, other natural ligands of ICAM-1 include fibrin, rhinovirus, poliovirus, HIV, 
some bacteria112, and Plasmodium falciparum-infected erythrocytes during malarial 
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infection113. Future work should address potential role of CAM-mediated endocytosis, 
along with newfound player ASM, in the uptake of these molecules and organisms by 
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